Bioespectrometría y Metabolómica ; Bioespectrometry and metabolomics
Biospectra
Hospital Universitario Príncipe de Asturias
Alcalá de Henares, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Príncipe de Asturias (24)
2023
-
Induction of more aggressive tumoral phenotypes in LNCaP and PC3 cells by serum exosomes from prostate cancer patients
International Journal of Cancer, Vol. 153, Núm. 10, pp. 1829-1841
2022
-
Chronic Venous Disease in Pregnant Women Causes an Increase in ILK in the Placental Villi Associated with a Decrease in E-Cadherin
Journal of Personalized Medicine, Vol. 12, Núm. 2
-
Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity
Biomedicines, Vol. 10, Núm. 3
2018
-
Does [-2]Pro-Prostate Specific Antigen Meet the Criteria to Justify Its Inclusion in the Clinical Decision-Making Process?
Urologia Internationalis, Vol. 100, Núm. 2, pp. 146-154
-
Validación del índice de salud prostática en un modelo predictivo de cáncer de próstata
Actas Urologicas Espanolas, Vol. 42, Núm. 1, pp. 25-32
2016
-
Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer
Oncotarget, Vol. 7, Núm. 32, pp. 52195-52206
2015
-
VIP induces NF-κB1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells
Cellular Signalling, Vol. 27, Núm. 2, pp. 236-244
2014
-
Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression
International Journal of Biochemistry and Cell Biology, Vol. 53, pp. 295-301
2013
-
Antitumoral effects of vasoactive intestinal peptide in human renal cell carcinoma xenografts in athymic nude mice
Cancer Letters, Vol. 336, Núm. 1, pp. 196-203
-
Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer
International Journal of Cancer, Vol. 132, Núm. 4, pp. 755-765
-
Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma
Molecular and Cellular Endocrinology, Vol. 365, Núm. 2, pp. 212-222
2012
-
Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cells
Peptides, Vol. 38, Núm. 2, pp. 275-281
-
Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance
Histology and Histopathology, Vol. 27, Núm. 8, pp. 1093-1101
-
Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation
Biochimica et Biophysica Acta - Molecular Cell Research, Vol. 1823, Núm. 10, pp. 1676-1685
2010
-
Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer
Peptides, Vol. 31, Núm. 11, pp. 2035-2045
-
Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1
Cancer Letters, Vol. 299, Núm. 1, pp. 11-21
2009
-
Multifunctional role of VIP in prostate cancer progression in a xenograft model: Suppression by curcumin and COX-2 inhibitor NS-398
Peptides, Vol. 30, Núm. 12, pp. 2357-2364
-
Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells
Prostate, Vol. 69, Núm. 7, pp. 774-786
2007
-
Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone
International Journal of Oncology, Vol. 31, Núm. 5, pp. 1223-1230
-
Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-κB in human prostate cell lines. Differential time-dependent responses in cancer progression
Molecular and Cellular Endocrinology, Vol. 270, Núm. 1-2, pp. 8-16